Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

E-Poster Display

1134P - BRAF codon 600 mutations in patients diagnosed with melanoma in the UK; An audit to assess variation in mutation frequency & methods between clinical testing centres

Date

17 Sep 2020

Session

E-Poster Display

Topics

Targeted Therapy

Tumour Site

Melanoma

Presenters

Michail Charakidis

Citation

Annals of Oncology (2020) 31 (suppl_4): S672-S710. 10.1016/annonc/annonc280

Authors

M. Charakidis1, A. Backen1, A.J. Wallace2, F. Blackhall1, X. Wang3, P. Lorigan1

Author affiliations

  • 1 Department Of Medical Oncology, The Christie NHS Foundation Trust, M204BX - Manchester/GB
  • 2 Manchester Centre For Genomics Medicine, St Mary’s Hospital, M139WL - Manchester/GB
  • 3 Department Of Analytics And Statistics, The Christie NHS Foundation Trust, M204BX - Manchester/GB

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 1134P

Background

The published frequency of the BRAF p.V600 mutations in patients with melanoma is approximately 40% and is dependent on age and melanoma subtype. BRAF status is a key predictive factor for response to targeted therapy and immunotherapy and there is increasing evidence that it is also prognostic. Mutation testing is a standard of care for patients with resected Stage 3 and for Stage 4 disease, to inform treatment choice. There are currently a variety of validated and approved methods for BRAF testing. The primary aim of this study was to identify all clinical laboratories in the UK performing BRAF testing for melanoma and examine the assays used, positivity rates and turnaround time.

Methods

This was a retrospective audit of laboratories performing BRAF gene mutational analysis in melanoma samples in the UK. 14 out of the 18 identified laboratories participated. Methodologies used and anonymised results for samples tested Jan-Dec 2019 were collected.

Results

4050 results were analysed. The median BRAF positivity rate amongst all laboratories was 34% (range 23-41%). The median turnaround time for reporting results was 7 calendar days. 6 laboratories used only one method of testing and 8 laboratories used more than one. The types of tests used varied between the testing centres. All laboratories are able to detect clinically important BRAF p.V600E and p.V600K mutations. Men (p= 0.0354) and younger patients (p <0.001) had higher rates of BRAF mutation. the range of median age per laboratory was 65-72.

Conclusions

The median reported BRAF positivity rates in the UK is lower than published and there is a wide range. The reasons for the difference in the positivity rates are likely multiple but could potentially have an impact on treatment options offered to patients. Further research is required to identify the reasons for these differences. This will include collaboration with the UK National External Quality Assessment Scheme to optimise the methodologies used across centres, aiming for more consistent results across the board.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The Christie NHS Foundation Trust.

Funding

Has not received any funding.

Disclosure

M. Charakidis: Honoraria (self), To attend virtual ASCO: Novartis. F.H. Blackhall: Honoraria (self): Roche. P. Lorigan: Honoraria (self), Advisory/Consultancy, Speaker Bureau/Expert testimony: Novartis; Honoraria (self), Advisory/Consultancy, Speaker Bureau/Expert testimony, Research grant/Funding (institution), Travel/Accommodation/Expenses: BMS; Honoraria (self), Advisory/Consultancy, Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: MSD. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.